[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2022001085A - Anticuerpos anti-c1s humanizados y metodos para usarlos. - Google Patents

Anticuerpos anti-c1s humanizados y metodos para usarlos.

Info

Publication number
MX2022001085A
MX2022001085A MX2022001085A MX2022001085A MX2022001085A MX 2022001085 A MX2022001085 A MX 2022001085A MX 2022001085 A MX2022001085 A MX 2022001085A MX 2022001085 A MX2022001085 A MX 2022001085A MX 2022001085 A MX2022001085 A MX 2022001085A
Authority
MX
Mexico
Prior art keywords
antibodies
humanized anti
present disclosure
disclosure provides
methods
Prior art date
Application number
MX2022001085A
Other languages
English (en)
Inventor
Sandip Panicker
Graham Parry
Original Assignee
Bioverativ Usa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioverativ Usa Inc filed Critical Bioverativ Usa Inc
Publication of MX2022001085A publication Critical patent/MX2022001085A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21106—Hepsin (3.4.21.106)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente descripción proporciona anticuerpos anti-C1s humanizados. La presente descripción proporciona ácidos nucleicos que comprenden secuencias de nucleótidos que codifican los anticuerpos anti-C1s humanizados; y las células hospedadoras que comprenden los ácidos nucleicos. La presente descripción proporciona composiciones que comprenden los anticuerpos anti-C1s humanizados. La presente descripción proporciona métodos de uso de los anticuerpos anti-C1s humanizados.
MX2022001085A 2015-04-06 2017-10-05 Anticuerpos anti-c1s humanizados y metodos para usarlos. MX2022001085A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562143636P 2015-04-06 2015-04-06
US201562200997P 2015-08-04 2015-08-04

Publications (1)

Publication Number Publication Date
MX2022001085A true MX2022001085A (es) 2022-02-14

Family

ID=57073330

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017012834A MX2017012834A (es) 2015-04-06 2016-04-05 Anticuerpos anti-c1s humanizados y metodos para usarlos.
MX2022001085A MX2022001085A (es) 2015-04-06 2017-10-05 Anticuerpos anti-c1s humanizados y metodos para usarlos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2017012834A MX2017012834A (es) 2015-04-06 2016-04-05 Anticuerpos anti-c1s humanizados y metodos para usarlos.

Country Status (27)

Country Link
US (3) US10729767B2 (es)
EP (2) EP4212175A1 (es)
JP (4) JP7005483B2 (es)
KR (1) KR20180006379A (es)
CN (2) CN108348598B (es)
AU (2) AU2016246452B2 (es)
BR (1) BR112017021289A2 (es)
CA (1) CA2981321A1 (es)
CL (1) CL2017002514A1 (es)
CO (1) CO2017011238A2 (es)
DK (1) DK3280440T5 (es)
EA (1) EA201792080A1 (es)
ES (1) ES2938359T3 (es)
FI (1) FI3280440T3 (es)
HK (2) HK1250930A1 (es)
HR (1) HRP20230093T1 (es)
HU (1) HUE061076T2 (es)
IL (2) IL298180A (es)
LT (1) LT3280440T (es)
MX (2) MX2017012834A (es)
PH (1) PH12017501815A1 (es)
PL (1) PL3280440T3 (es)
PT (1) PT3280440T (es)
RS (1) RS63956B1 (es)
SG (2) SG10201909180SA (es)
SI (1) SI3280440T1 (es)
WO (1) WO2016164358A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11236168B2 (en) 2012-08-24 2022-02-01 Chugai Seiyaku Kabushiki Kaisha Mouse FcγammaRII-specific Fc antibody
WO2014066744A2 (en) 2012-10-25 2014-05-01 True North Therapeutics, Inc. Anti-complement c1s antibodies and uses thereof
WO2014071206A1 (en) 2012-11-02 2014-05-08 True North Therapeutics, Inc. Anti-complement c1s antibodies and uses thereof
CN113621057A (zh) 2013-04-02 2021-11-09 中外制药株式会社 Fc区变体
CN108348598B (zh) 2015-04-06 2023-09-01 比奥贝拉蒂美国公司 人源化抗C1s抗体及其使用方法
TWI846007B (zh) * 2016-10-12 2024-06-21 美商生物維瑞提夫美國公司 抗Ｃ１ｓ抗體及其使用方法
EP3710589A4 (en) 2017-11-14 2021-11-10 Chugai Seiyaku Kabushiki Kaisha ANTI-C1S ANTIBODIES AND METHODS OF USE
CA3094312A1 (en) * 2018-04-13 2019-10-17 Chugai Seiyaku Kabushiki Kaisha Anti-complement component antibodies and methods of use
JP2023536904A (ja) 2020-08-06 2023-08-30 バイオベラティブ・ユーエスエイ・インコーポレイテッド 補体が媒介する疾患を有する対象における炎症性サイトカインおよび疲労
CN117241828A (zh) 2021-03-31 2023-12-15 美国比奥维拉迪维股份有限公司 减少冷凝集素病患者的手术相关溶血
EP4337332A2 (en) 2021-07-13 2024-03-20 Mabwell Therapeutics Inc. Anti-c1s antibodies and uses thereof
US20240117021A1 (en) 2022-06-15 2024-04-11 Bioverativ Usa Inc. Anti-complement c1s antibody formulation
US20240025978A1 (en) 2022-06-24 2024-01-25 Bioverativ Usa Inc. Methods for treating complement-mediated diseases
WO2024192389A2 (en) 2023-03-16 2024-09-19 Genzyme Corporation Treatment of dry age-related macular degeneration

Family Cites Families (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS60192263A (ja) 1984-03-13 1985-09-30 Teijin Ltd 免疫複合体測定用標準物質及びそれを用いた免疫複合体の測定法
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
ATE243754T1 (de) 1987-05-21 2003-07-15 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
AU663725B2 (en) 1991-08-20 1995-10-19 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Adenovirus mediated transfer of genes to the gastrointestinal tract
DE69229477T2 (de) 1991-09-23 1999-12-09 Cambridge Antibody Technology Ltd., Melbourn Methoden zur Herstellung humanisierter Antikörper
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
DK0617706T3 (da) 1991-11-25 2001-11-12 Enzon Inc Multivalente antigenbindende proteiner
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
AU680459B2 (en) 1992-12-03 1997-07-31 Genzyme Corporation Gene therapy for cystic fibrosis
CA2115811A1 (en) 1993-02-17 1994-08-18 Claus Krebber A method for in vivo selection of ligand-binding proteins
WO1995000655A1 (en) 1993-06-24 1995-01-05 Mc Master University Adenovirus vectors for gene therapy
DE69429816T2 (de) 1993-09-01 2002-09-19 Stichting Sanquin Bloedvoorziening, Amsterdam C1-Esterasehemmer zur Verringerung von Myokardschäden bei akutem Herzinfarkt
ES2328585T3 (es) 1993-10-25 2009-11-16 Canji, Inc. Vector de adenovirus recombinante y metodo de utilizacion.
JP3522285B2 (ja) 1994-12-09 2004-04-26 インペリアル カレッジ イノベイションズ リミテッド 遺伝子の同定
US7083786B2 (en) 1997-04-03 2006-08-01 Jensenius Jens Chr MASP-2, a complement-fixing enzyme, and uses for it
US6080849A (en) 1997-09-10 2000-06-27 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
JP2003529536A (ja) 1999-02-09 2003-10-07 ３−ディメンショナル ファーマシューティカルズ， インコーポレイテッド Ｃ１ｓ介在疾患および状態の処置法、およびそれのための化合物および組成物
WO2000064327A2 (en) 1999-04-26 2000-11-02 Duke University Inhibition of complement action
WO2001013945A1 (en) 1999-08-23 2001-03-01 Biocrystal Ltd. Methods and compositions for immunotherapy of b cell involvement in promotion of a disease condition comprising multiple sclerosis
EP1252184B1 (en) 2000-01-31 2008-01-02 Pharming Intellectual Property B.V. Human c1 inhibitor produced in the milk of transgenic mammals
PT1265929E (pt) 2000-03-23 2009-10-15 Genentech Inc Inibidores anti-c2/c2a de activação complementar
US7071299B2 (en) 2000-06-21 2006-07-04 Zymogenetics, Inc. Peptide and polypeptide inhibitors of complement C1s
GB0105924D0 (en) 2001-03-09 2001-04-25 Microscience Ltd Promoter
CA2454562A1 (en) 2001-07-26 2003-02-06 Alexion Pharmaceuticals, Inc. Method of improving cognitive function
US20080206242A1 (en) 2002-03-01 2008-08-28 Xencor, Inc. Method of treatment of th2-mediated conditions using optimized anti-cd30 antibodies
SE0202880D0 (sv) 2002-07-26 2002-09-30 Wieslab Ab Complement system deficiency assay
US7666627B2 (en) 2002-08-08 2010-02-23 Targetex Kft. Folded recombinant catalytic fragments of multidomain serine proteases, preparation and uses thereof
EP1545611B1 (en) 2002-09-06 2016-11-09 Alexion Pharmaceuticals, Inc. Method of treatment of asthma using antibodies to complement component c5
US20050271660A1 (en) 2002-09-06 2005-12-08 Alexion Pharmaceuticals, Inc. Nebulization of monoclonal antibodies for treating pulmonary diseases
US7361339B2 (en) 2003-01-09 2008-04-22 Alexion Pharmaceuticals, Inc. Methods for reducing morality associated with acute myocardial infarction
CA2524534C (en) 2003-05-15 2012-12-11 Sek Chung Fung Methods and compositions for the prevention and treatment of sepsis
US7482376B2 (en) 2003-07-03 2009-01-27 3-Dimensional Pharmaceuticals, Inc. Conjugated complement cascade inhibitors
WO2005014849A2 (en) 2003-07-03 2005-02-17 Euro-Celtique, S.A. Genes associated with responses to neuropathic pain
US8501705B2 (en) 2003-09-11 2013-08-06 The Board Of Regents Of The University Of Texas System Methods and materials for treating autoimmune and/or complement mediated diseases and conditions
US7923010B2 (en) 2003-09-11 2011-04-12 The Board Of Regents Of The University Of Texas System Methods and materials for treating autoimmune diseases and conditions
AU2003271186A1 (en) 2003-10-14 2005-04-27 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
AU2004297616B2 (en) * 2003-12-04 2008-12-18 Xencor, Inc. Methods of generating variant proteins with increased host string content and compositions thereof
US7803931B2 (en) 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
DK1737891T3 (da) 2004-04-13 2013-03-25 Hoffmann La Roche Anti-p-selectin-antistoffer
US8840893B2 (en) 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
LT1753456T (lt) 2004-06-10 2016-11-10 Omeros Corporation Ligų, susijusių su nuo masp-2 priklausomu komplemento aktyvinimu, gydymo būdai
US7919094B2 (en) 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
WO2005123776A1 (en) 2004-06-10 2005-12-29 Omeros Corporation Methods for treating conditions associated with lectin-dependent complement activation
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
EP1819731A4 (en) 2004-12-08 2013-02-13 Immunomedics Inc METHOD AND COMPOSITION FOR IMMUNOTHERAPY AND FOR THE DETECTION OF INFLAMMATORY AND DYSEGRATIVE IMMUNE DISEASES, INFECTION DISEASES, PATHOLOGICAL ANGIOGENESIS AND CANCER
MX2007011293A (es) 2005-03-16 2008-03-18 Johnson & Johnson Tiofenosulfoximinas novedosas para el tratamiento de enfermedades y condiciones mediadas por el complemento.
US7897561B2 (en) 2005-06-06 2011-03-01 Girish J. Kotwal Methods for treatment or prophylaxis of atherosclerosis and reperfusion injury
NZ606504A (en) 2005-10-21 2014-08-29 Catalyst Biosciences Inc Modified proteases that inhibit complement activation
US9480658B2 (en) 2005-12-09 2016-11-01 The Board Of Trustees Of The Leland Stanford Junior University Modulation of synaptic maintenance
US8148330B2 (en) 2005-12-09 2012-04-03 The Board Of Trustees Of The Leland Stanford Junior University Modulation of synaptic maintenance
EP2380587B1 (en) 2005-12-21 2017-10-25 Pharming Intellectual Property B.V. Use of C1 inhibitor for the prevention of ischemia-reperfusion injury
FR2897868B1 (fr) 2006-02-24 2012-08-31 Lab Francais Du Fractionnement Anticorps anti-idiotypiques neutralisant l'activite inhibitrice d'un anticorps inhibiteur dirige contre le domaine c1 du facteur viii.
HUE026496T2 (en) 2006-03-08 2016-06-28 Archemix Llc Complement-binding aptamers and anti-C5 agents for treating eye diseases
SI2061810T1 (sl) 2006-09-05 2015-04-30 Alexion Pharmaceuticals, Inc. Postopki in sestavki za zdravljenje s protitelesi povezanih nevropatij
CA2666466C (en) 2006-10-10 2017-11-14 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Complement inhibition for improved nerve regeneration
US8378138B2 (en) 2006-12-19 2013-02-19 The University of Hong Kong & Versitech Limited Synthetic ion channels
EP2148691B1 (en) 2007-02-05 2015-05-20 Apellis Pharmaceuticals, Inc. Compstatin analogues for use in the treatment of inflammatory conditions of the respiratory system
US8192742B2 (en) 2007-03-23 2012-06-05 NovelMed Therapeutics Method of inhibiting complement activation with human anti-factor C3 antibodies and use thereof
EP2502937B1 (en) 2007-07-16 2016-04-06 Genentech, Inc. Anti-CD 79b Antibodies And Immunoconjugates And Methods Of Use
AU2008299779B2 (en) 2007-08-03 2013-05-16 Genentech, Inc. Humanized anti-FGF19 antagonists and methods using same
US20110190221A1 (en) 2008-03-28 2011-08-04 Apellis Ag Modulation and repletion/enhancement of the complement system for treatment of trauma
AU2009239437B2 (en) 2008-04-25 2014-11-13 University Of Washington Levels of BCMA protein expression on B cells and use in diagnostic methods
US20090324585A1 (en) 2008-06-12 2009-12-31 The Trustees of the Leland Standford Junior University Complement inhibitory agents as therapeutics in posttraumatic and degenerative arthritis
NZ614351A (en) 2008-11-10 2015-05-29 Alexion Pharma Inc Methods and compositions for treating complement-associated disorders
EP2353005B1 (en) 2008-12-01 2018-10-03 The Board of Trustees of The Leland Stanford Junior University Methods and compositions for detection of complement fixing antibodies
US8401799B2 (en) 2008-12-05 2013-03-19 Lpath, Inc. Antibody design using anti-lipid antibody crystal structures
US20110002931A1 (en) 2009-06-23 2011-01-06 Alexion Pharmaceuticals, Inc. Bispecific antibodies that bind to complement proteins
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
CN106390117A (zh) 2009-10-16 2017-02-15 奥默罗斯公司 通过抑制masp‑2依赖性补体活化治疗弥散性血管内凝血的方法
WO2011102342A1 (ja) 2010-02-16 2011-08-25 国立大学法人京都工芸繊維大学 抗体固定化担体、抗体固定化担体の製造方法および当該抗体固定化担体の利用
KR20130009784A (ko) 2010-03-01 2013-01-23 알렉시온 파마슈티칼스, 인코포레이티드 악성 위축성 구진증을 치료하는 방법 및 조성물
WO2011137395A1 (en) 2010-04-30 2011-11-03 Rother Russell P Anti-c5a antibodies and methods for using the antibodies
KR20130135028A (ko) 2010-05-17 2013-12-10 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 동물로부터 단일클론 항체의 고속 분리
CN103249432A (zh) 2010-06-22 2013-08-14 科罗拉多大学董事会,法人团体 补体成分3的C3d片段的抗体
WO2011163394A2 (en) 2010-06-22 2011-12-29 Apellis Pharmaceuticals, Inc. Compstatin analogs for treatment of neuropathic pain
TWI560199B (en) 2010-08-31 2016-12-01 Sanofi Sa Peptide or peptide complex binding to α2 integrin and methods and uses involving the same
TW201241008A (en) 2010-10-01 2012-10-16 Alexion Pharma Inc Polypeptides that bind to human complement component C5
US8865164B2 (en) 2010-11-02 2014-10-21 Kypha, Inc. Detecting complement activation
KR20220011811A (ko) 2010-12-06 2022-01-28 씨젠 인크. Ｌｉｖ-１에 대한 인간화 항체 및 이의 암을 치료하기 위한 용도
AU2012239889B2 (en) 2011-04-08 2015-09-03 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
DK2704743T3 (en) 2011-05-04 2020-05-25 Omeros Corp Compositions for inhibiting masp-2 dependent complement acitivation
US9289467B2 (en) 2011-08-10 2016-03-22 Case Western Reserve University Compositions and methods for treating bone conditions
AU2012318275B2 (en) 2011-12-22 2016-05-19 Csl Behring Gmbh Use of C1-inhibitor for the treatment of secondary edema of the central nervous system
JP6081699B2 (ja) 2011-12-28 2017-02-15 雅史 溝上 Ｉｌ−２８ｂの分析方法
WO2014066744A2 (en) 2012-10-25 2014-05-01 True North Therapeutics, Inc. Anti-complement c1s antibodies and uses thereof
WO2014071206A1 (en) 2012-11-02 2014-05-08 True North Therapeutics, Inc. Anti-complement c1s antibodies and uses thereof
US10280215B2 (en) 2013-01-31 2019-05-07 Seoul National University R&Db Foundation Anti-C5 antibodies and methods of treating complement-related diseases
CA2916521C (en) 2013-07-09 2023-03-07 Annexon, Inc. Anti-complement factor c1q antibodies and uses thereof
WO2015084999A1 (en) 2013-12-06 2015-06-11 True North Therapeutics, Inc. Complement component biomarker assays
CN108348598B (zh) 2015-04-06 2023-09-01 比奥贝拉蒂美国公司 人源化抗C1s抗体及其使用方法
CA2990662A1 (en) 2015-06-26 2016-12-29 Bioverativ Usa Inc. Methods of treating autoimmune and alloimmune disorders
TWI846007B (zh) 2016-10-12 2024-06-21 美商生物維瑞提夫美國公司 抗Ｃ１ｓ抗體及其使用方法
US20210115116A1 (en) 2017-03-14 2021-04-22 Bioverativ Usa Inc. Methods for treating complement-mediated diseases and disorders

Also Published As

Publication number Publication date
IL254670B2 (en) 2023-04-01
IL254670A0 (en) 2017-11-30
ES2938359T3 (es) 2023-04-10
HK1259251A1 (zh) 2019-11-29
EP3280440A4 (en) 2018-08-29
JP7005483B2 (ja) 2022-02-10
JP7518114B2 (ja) 2024-07-17
EP3280440B1 (en) 2022-11-16
SG11201707886WA (en) 2017-10-30
HRP20230093T1 (hr) 2023-03-31
US10729767B2 (en) 2020-08-04
JP2021006544A (ja) 2021-01-21
DK3280440T5 (da) 2024-10-07
AU2022203679A1 (en) 2022-06-16
CA2981321A1 (en) 2016-10-13
JP7153696B2 (ja) 2022-10-14
RS63956B1 (sr) 2023-02-28
FI3280440T3 (fi) 2023-03-09
JP2018513213A (ja) 2018-05-24
US11246926B2 (en) 2022-02-15
PL3280440T3 (pl) 2023-06-19
KR20180006379A (ko) 2018-01-17
CN117285634A (zh) 2023-12-26
LT3280440T (lt) 2023-02-27
US20230218753A1 (en) 2023-07-13
JP2022078221A (ja) 2022-05-24
EP4212175A1 (en) 2023-07-19
IL298180A (en) 2023-01-01
CN108348598B (zh) 2023-09-01
EP3280440A1 (en) 2018-02-14
SI3280440T1 (sl) 2023-03-31
CO2017011238A2 (es) 2018-01-16
PT3280440T (pt) 2023-02-14
BR112017021289A2 (pt) 2018-06-26
CN108348598A (zh) 2018-07-31
AU2016246452B2 (en) 2022-03-10
DK3280440T3 (da) 2023-02-20
AU2016246452A1 (en) 2017-10-19
US20200405852A1 (en) 2020-12-31
WO2016164358A1 (en) 2016-10-13
JP2024133591A (ja) 2024-10-02
MX2017012834A (es) 2018-05-28
HK1250930A1 (zh) 2019-01-18
HUE061076T2 (hu) 2023-05-28
US20180092974A1 (en) 2018-04-05
CL2017002514A1 (es) 2018-04-20
EA201792080A1 (ru) 2018-03-30
PH12017501815A1 (en) 2018-04-23
IL254670B (en) 2022-12-01
SG10201909180SA (en) 2019-11-28

Similar Documents

Publication Publication Date Title
MX2022001085A (es) Anticuerpos anti-c1s humanizados y metodos para usarlos.
PH12019500540A1 (en) Anti-pd-1 antibodies and their uses
PH12018502456A1 (en) Anti-cd04 antibodies and their uses
PH12019501357A1 (en) Anti-ox40 antibodies and their uses
PH12019500789A1 (en) Anti-c1s antibodies and methods of use thereof
EP3741849A3 (en) Protease variants and polynucleotides encoding same
MX2017014125A (es) Variantes de alfa-amilasa y polinucleotidos que codifican las mismas.
PH12017500861A1 (en) Anti-interleukin-33 antibodies and uses thereof
MX2017007731A (es) Composiciones de detergente, variantes de lipasa y polinucleotidos que codifican las mismas.
MX2018006973A (es) Anticuerpos anti-cd73 humanizados.
PH12017501115A1 (en) Anti-myostatin antibodies, polypeptides containing variant fc regions, and method of use
EP3741848A3 (en) Protease variants and polynucleotides encoding same
WO2016066756A3 (en) Protease variants and polynucleotides encoding same
WO2016066757A3 (en) Protease variants and polynucleotides encoding same
PE20210107A1 (es) Anticuerpos anti-cd3 y metodos de uso
MX2019000140A (es) Variantes de xilanasa y polinucleotidos que las codifican.
WO2016065349A8 (en) Short non-coding protein regulatory rnas (sprrnas) and methods of use
MX2024000004A (es) Proteinas de fusion de inhibidor de tripsina urinaria (uti).
EP3739045A3 (en) Cellobiohydrolase variants and polynucleotides encoding same
TW201614071A (en) Aptamer specific to colorectal cancer stem cell and application thereof
TW201614070A (en) Aptamer specific to colorectal cancer cell and application thereof